abstract |
The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, it is beneficial to modulate PD-1, PD-L1, and / or PD-L2 activity using the novel human anti-PD-1, PD-L1 and PD- The present invention relates to compositions and methods for diagnosing, prognosing and treating conditions (e. G. Persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory diseases and tumors). |